The Role of 68Ga-FAPI PET/CT in Breast Cancer Response Assessment and Follow-Up

Yael Eshet; Noam Tau; Keren Levanon; Rinat Bernstein-Molho; Ofer Globus; Amit Itay; Tal Shapira; Cecilie Oedegaard; Michal Eifer; Tima Davidson; Meital Nidam; Einav Gal-Yam; Liran Domachevsky

doi:10.1097/RLU.0000000000004744

The Role of ⁶⁸Ga-FAPI PET/CT in Breast Cancer Response Assessment and Follow-Up

Yael Eshet^*, Noam Tau, Keren Levanon, Rinat Bernstein-Molho, Ofer Globus, Amit Itay, Tal Shapira, Cecilie Oedegaard, Michal Eifer, Tima Davidson, Meital Nidam, Einav Gal-Yam, Liran Domachevsky

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

9 Scopus citations

Abstract

Purpose 68Ga-fibroblast activation protein inhibitor (FAPI), a new PET/CT radiotracer targeting cancer-associated fibroblasts in tumor microenvironment, can detect many types of cancer. We aimed to assess whether it can also be used for response assessment and follow-up. Methods We followed up patients with FAPI-avid invasive lobular breast cancer (ILC) before and after treatment changes and correlated qualitative maximal intensity projection images and quantitative tumor volume with CT results and blood tumor biomarkers. Results Six consenting ILC breast cancer patients (53 ± 8 years old) underwent a total of 24 scans (baseline for each patient and 2-4 follow-up scans). We found a strong correlation between 68Ga-FAPI tumor volume and blood biomarkers (r = 0.7, P < 0.01), but weak correlation between CT and 68Ga-FAPI maximal intensity projection-based qualitative response assessment. Conclusions We found a strong correlation between ILC progression and regression (as assessed by blood biomarkers) and 68Ga-FAPI tumor volume. 68Ga-FAPI PET/CT could possibly be used for disease response assessment and follow-up.

Original language	English
Pages (from-to)	685-688
Number of pages	4
Journal	Clinical Nuclear Medicine
Volume	48
Issue number	8
DOIs	https://doi.org/10.1097/RLU.0000000000004744
State	Published - 1 Aug 2023

Funding

Funders	Funder number
Isotopia Molecular Imaging Ltd
Sheba Medical Center

Keywords

FAPI-04
PET/CT
breast neoplasms
carcinoma
follow-up
lobular
response assessment

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1097/RLU.0000000000004744

Cite this

@article{e26d554d6da4472dbe9c3ebcdd62477b,

title = "The Role of 68Ga-FAPI PET/CT in Breast Cancer Response Assessment and Follow-Up",

abstract = "Purpose 68Ga-fibroblast activation protein inhibitor (FAPI), a new PET/CT radiotracer targeting cancer-associated fibroblasts in tumor microenvironment, can detect many types of cancer. We aimed to assess whether it can also be used for response assessment and follow-up. Methods We followed up patients with FAPI-avid invasive lobular breast cancer (ILC) before and after treatment changes and correlated qualitative maximal intensity projection images and quantitative tumor volume with CT results and blood tumor biomarkers. Results Six consenting ILC breast cancer patients (53 ± 8 years old) underwent a total of 24 scans (baseline for each patient and 2-4 follow-up scans). We found a strong correlation between 68Ga-FAPI tumor volume and blood biomarkers (r = 0.7, P < 0.01), but weak correlation between CT and 68Ga-FAPI maximal intensity projection-based qualitative response assessment. Conclusions We found a strong correlation between ILC progression and regression (as assessed by blood biomarkers) and 68Ga-FAPI tumor volume. 68Ga-FAPI PET/CT could possibly be used for disease response assessment and follow-up.",

keywords = "FAPI-04, PET/CT, breast neoplasms, carcinoma, follow-up, lobular, response assessment",

author = "Yael Eshet and Noam Tau and Keren Levanon and Rinat Bernstein-Molho and Ofer Globus and Amit Itay and Tal Shapira and Cecilie Oedegaard and Michal Eifer and Tima Davidson and Meital Nidam and Einav Gal-Yam and Liran Domachevsky",

year = "2023",

month = aug,

day = "1",

doi = "10.1097/RLU.0000000000004744",

language = "אנגלית",

volume = "48",

pages = "685--688",

journal = "Clinical Nuclear Medicine",

issn = "0363-9762",

publisher = "Lippincott Williams and Wilkins Ltd.",

number = "8",

}

TY - JOUR

T1 - The Role of 68Ga-FAPI PET/CT in Breast Cancer Response Assessment and Follow-Up

AU - Eshet, Yael

AU - Tau, Noam

AU - Levanon, Keren

AU - Bernstein-Molho, Rinat

AU - Globus, Ofer

AU - Itay, Amit

AU - Shapira, Tal

AU - Oedegaard, Cecilie

AU - Eifer, Michal

AU - Davidson, Tima

AU - Nidam, Meital

AU - Gal-Yam, Einav

AU - Domachevsky, Liran

PY - 2023/8/1

Y1 - 2023/8/1

N2 - Purpose 68Ga-fibroblast activation protein inhibitor (FAPI), a new PET/CT radiotracer targeting cancer-associated fibroblasts in tumor microenvironment, can detect many types of cancer. We aimed to assess whether it can also be used for response assessment and follow-up. Methods We followed up patients with FAPI-avid invasive lobular breast cancer (ILC) before and after treatment changes and correlated qualitative maximal intensity projection images and quantitative tumor volume with CT results and blood tumor biomarkers. Results Six consenting ILC breast cancer patients (53 ± 8 years old) underwent a total of 24 scans (baseline for each patient and 2-4 follow-up scans). We found a strong correlation between 68Ga-FAPI tumor volume and blood biomarkers (r = 0.7, P < 0.01), but weak correlation between CT and 68Ga-FAPI maximal intensity projection-based qualitative response assessment. Conclusions We found a strong correlation between ILC progression and regression (as assessed by blood biomarkers) and 68Ga-FAPI tumor volume. 68Ga-FAPI PET/CT could possibly be used for disease response assessment and follow-up.

AB - Purpose 68Ga-fibroblast activation protein inhibitor (FAPI), a new PET/CT radiotracer targeting cancer-associated fibroblasts in tumor microenvironment, can detect many types of cancer. We aimed to assess whether it can also be used for response assessment and follow-up. Methods We followed up patients with FAPI-avid invasive lobular breast cancer (ILC) before and after treatment changes and correlated qualitative maximal intensity projection images and quantitative tumor volume with CT results and blood tumor biomarkers. Results Six consenting ILC breast cancer patients (53 ± 8 years old) underwent a total of 24 scans (baseline for each patient and 2-4 follow-up scans). We found a strong correlation between 68Ga-FAPI tumor volume and blood biomarkers (r = 0.7, P < 0.01), but weak correlation between CT and 68Ga-FAPI maximal intensity projection-based qualitative response assessment. Conclusions We found a strong correlation between ILC progression and regression (as assessed by blood biomarkers) and 68Ga-FAPI tumor volume. 68Ga-FAPI PET/CT could possibly be used for disease response assessment and follow-up.

KW - FAPI-04

KW - PET/CT

KW - breast neoplasms

KW - carcinoma

KW - follow-up

KW - lobular

KW - response assessment

UR - http://www.scopus.com/inward/record.url?scp=85164230976&partnerID=8YFLogxK

U2 - 10.1097/RLU.0000000000004744

DO - 10.1097/RLU.0000000000004744

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???

C2 - 37339456

AN - SCOPUS:85164230976

SN - 0363-9762

VL - 48

SP - 685

EP - 688

JO - Clinical Nuclear Medicine

JF - Clinical Nuclear Medicine

IS - 8

ER -